MIRA Pharmaceuticals' oral ketamine analog, Ketamir-2, outperforms Gabapentin and Pregabalin in preclinical studies for neuropathic pain relief.

MIRA Pharmaceuticals has revealed that its oral ketamine analog, Ketamir-2, surpassed FDA-approved medications Gabapentin and Pregabalin in preclinical studies for neuropathic pain relief. This non-opioid treatment shows promise without the risk of addiction or severe side effects. MIRA plans to submit an Investigational New Drug application by year-end and initiate Phase 1 clinical trials in early 2025.

October 21, 2024
6 Articles